40% of NSCLC carry allele-Specific HLA Loss(HLA-I LOH), which is related to a raised neoantigen burden, PD-L1 positivity, and poor response to ICIs treatment (52, 53). The gene discussed is CD274; the disease is non-small cell lung carcinoma.